Written answers
Tuesday, 18 December 2018
Department of Health
Addiction Treatment Services
John Curran (Dublin Mid West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
327. To ask the Minister for Health the number of new clients who have been granted access to naloxone to date in 2018. [52690/18]
Catherine Byrne (Dublin South Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source
As this is a service matter, it has been referred to the HSE for attention and direct reply to the Deputy.
John Curran (Dublin Mid West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
328. To ask the Minister for Health if regulations to allow for the introduction of buprenorphine naloxone, buprenorphine products have been agreed and introduced. [52691/18]
Catherine Byrne (Dublin South Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source
On 22 November 2017, I signed the Misuse of Drugs (Supervision of Prescription and Supply of Methadone and Medicinal Products containing Buprenorphine authorised for Opioid Substitution Treatment) Regulations 2017 (S.I. No. 522 of 2017). The Regulations added certain buprenorphine medicinal products to the schedule of products which can be prescribed for opioid substitution treatment.
John Curran (Dublin Mid West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
329. To ask the Minister for Health if he will report on the working group to progress increased access to buprenorphine naloxone and buprenorphine products. [52692/18]
Catherine Byrne (Dublin South Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source
In January 2016, the Director General of the HSE submitted the final report of the Opioid Substitution Implementation Group to the Minister of State with responsibility for the national drugs strategy. The report recommends the phased increased of access to buprenorphine/naloxone (Suboxone) for groups of patients in specific circumstances, subject to resourcing and the required legislation being enacted.
New Regulations, the Misuse of Drugs (Supervision of Prescription and Supply of Methadone and Medicinal Products containing Buprenorphine authorised for Opioid Substitution Treatment) Regulations 2017 came into effect on 22 November 2017. The purpose of these Regulations is to provide access to certain buprenorphine-based medicinal products for Opioid Substitution Treatment (including buprenorphine/naloxone and buprenorphine only) on the same statutory basis as methadone.
The Department of Health provided additional funding to the HSE in 2018 to expand availability of buprenorphine/naloxone for those not suited to OST.
John Curran (Dublin Mid West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
330. To ask the Minister for Health if he will report on the HSE training programme for addiction staff, level 2 general practitioners and pharmacists regarding buprenorphine naloxone and buprenorphine products. [52693/18]
John Curran (Dublin Mid West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
331. To ask the Minister for Health the increase in addiction residential treatment beds and additional treatment episodes provided to date in 2018. [52694/18]
John Curran (Dublin Mid West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
336. To ask the Minister for Health the average waiting time from referral to assessment for opioid substitution treatment. [52699/18]
Catherine Byrne (Dublin South Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source
I propose to take Questions Nos. 330, 331 and 336 together.
As these are service matters, they have been referred to the Health Service Executive for attention and direct reply to the Deputy.
No comments